BR112017001340A2 - vacinas antidengue e anticorpos - Google Patents

vacinas antidengue e anticorpos

Info

Publication number
BR112017001340A2
BR112017001340A2 BR112017001340A BR112017001340A BR112017001340A2 BR 112017001340 A2 BR112017001340 A2 BR 112017001340A2 BR 112017001340 A BR112017001340 A BR 112017001340A BR 112017001340 A BR112017001340 A BR 112017001340A BR 112017001340 A2 BR112017001340 A2 BR 112017001340A2
Authority
BR
Brazil
Prior art keywords
dimer
denv
ede
envelope
dengue virus
Prior art date
Application number
BR112017001340A
Other languages
English (en)
Inventor
Rouvinski Alexander
Augusto Rey Felix
Screaton Gavin
Barba-Spaeth Giovanna
MONGKOLSAPAYA Juthathip
Vaney Marie-Christine
GUARDADO-CALVO Pablo
Duquerroy Stéphane
Original Assignee
Imperial Innovations Ltd
Pasteur Institut
Univ Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd, Pasteur Institut, Univ Paris Sud filed Critical Imperial Innovations Ltd
Publication of BR112017001340A2 publication Critical patent/BR112017001340A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

trata-se de um epítopo de dímero de envelope (ede) de vírus da dengue, em que o ede: a) abrange os polipeptídeos de um dímero de polipeptídeo de envelope de vírus da dengue; e/ou b) é apresentado em um dímero de proteínas envelope; e/ou c) é formado a partir de resíduos consecutivos ou não consecutivos do dímero de polipeptídeo de envelope, em que o dímero é um homodímero ou heterodímero de polipeptídeos de envelope nativos e/ou mutantes, de qualquer um ou dois dentre denv-1, denv-2, denv-3 e denv-4. o ede pode ser um dímero de ectodomínio (se) de glicoproteína e de envelope de vírus da dengue recombinante estabilizado, em que o dímero é: covalentemente estabilizado com pelo menos uma ligação intercadeia dissulfeto entre os dois monômeros de se, e/ou covalentemente estabilizado com pelo menos um reticulador reativo com sulfidrila entre os dois monômeros de se, e/ou covalentemente estabilizado por ligação dos dois monômeros de se através de açúcares modificados; e/ou, covalentemente estabilizado por ser formado como uma cadeia de polipeptídeo única, opcionalmente com uma região ligante, opcionalmente uma região ligante rica em glicina serina, que separa as sequências de se, e/ou não covalentemente estabilizado por substituição de pelo menos um resíduo de aminoácido na sequência de aminoácidos de pelo menos um monômero de se com pelo menos um aminoácido de cadeia lateral volumoso, na interface de dímero ou no ligante de domínio 1 (d1)/domínio 3 (d3) de cada monômero. um composto, por exemplo, um anticorpo ou fragmento de anticorpo que pode neutralizar mais de um serotipo de vírus da dengue, por exemplo, um anticorpo que pode se ligar a um ede da invenção.
BR112017001340A 2014-07-23 2015-07-23 vacinas antidengue e anticorpos BR112017001340A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1413086.8A GB201413086D0 (en) 2014-07-23 2014-07-23 Methods
PCT/GB2015/052139 WO2016012800A1 (en) 2014-07-23 2015-07-23 Anti-dengue vaccines and antibodies

Publications (1)

Publication Number Publication Date
BR112017001340A2 true BR112017001340A2 (pt) 2017-11-14

Family

ID=51495027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001340A BR112017001340A2 (pt) 2014-07-23 2015-07-23 vacinas antidengue e anticorpos

Country Status (8)

Country Link
US (2) US11198706B2 (pt)
EP (3) EP4282483A2 (pt)
JP (2) JP7433744B2 (pt)
BR (1) BR112017001340A2 (pt)
CA (1) CA2988499A1 (pt)
GB (1) GB201413086D0 (pt)
MX (1) MX2017001017A (pt)
WO (1) WO2016012800A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
US10772948B2 (en) * 2015-10-07 2020-09-15 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus vaccines and diagnostics
US10772949B2 (en) 2016-02-16 2020-09-15 Albert Einstein College Of Medicine Dengue virus glycoprotein E DIII variants and uses thereof
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
AU2017277065A1 (en) * 2016-06-06 2019-01-17 Medizinische Universität Wien Method for the detection of an IgM antibody specific for a flavivirus in a sample
GB201610162D0 (en) * 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MY191894A (en) 2016-10-13 2022-07-18 Nat Univ Singapore Antibodies that bind zika virus envelope protein and uses thereof
US20190358313A1 (en) * 2016-12-23 2019-11-28 Expres2Ion Biotechnologies Aps New flavivirus vaccine
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
EP4010355A4 (en) * 2019-08-06 2024-02-21 Univ North Carolina Chapel Hill METHODS AND COMPOSITIONS FOR STABILIZED RECOMBINANT FLAVIVIRUS E PROTEIN DIMERS
EP4214229A1 (en) * 2020-09-15 2023-07-26 Duke University Coronavirus antibodies and uses thereof
US20220283088A1 (en) * 2021-02-03 2022-09-08 Joshua David Silver Viral load tester and applications thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006068A2 (en) * 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
CA2441986A1 (en) 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
WO2005003316A2 (en) 2003-07-02 2005-01-13 Ptc Therapeutics, Inc. Rna processing protein complexes and uses thereof
CA2894300A1 (en) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US20090311225A1 (en) * 2005-11-14 2009-12-17 Psma Development Company, Llc Compositions of and Methods of Using Stabilized PSMA Dimers
EP2653545A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
WO2009108797A1 (en) * 2008-02-27 2009-09-03 Mcw Research Foundation, Inc. An engineered cxcl12 alpha locked dimer polypeptide
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
BR112013009649A2 (pt) * 2010-10-29 2016-07-12 Merck Sharp & Dohme composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
CN108912215A (zh) 2012-04-02 2018-11-30 北卡罗来纳-查佩尔山大学 用于登革病毒表位的方法和组合物
US9267114B2 (en) * 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly

Also Published As

Publication number Publication date
JP7433744B2 (ja) 2024-02-20
JP2017529096A (ja) 2017-10-05
US20220127307A1 (en) 2022-04-28
EP3172229A1 (en) 2017-05-31
GB201413086D0 (en) 2014-09-03
US11198706B2 (en) 2021-12-14
JP2024037829A (ja) 2024-03-19
EP4223773A3 (en) 2023-12-06
MX2017001017A (es) 2017-08-10
CA2988499A1 (en) 2016-01-28
EP4223773A2 (en) 2023-08-09
EP3172229B1 (en) 2023-05-10
EP4282483A2 (en) 2023-11-29
WO2016012800A1 (en) 2016-01-28
US20180037611A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
BR112017001340A2 (pt) vacinas antidengue e anticorpos
BR112018075396A2 (pt) anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
AR094149A1 (es) Proteinas multifuncion que comprenden chm de clase i multivalente unido mediante disulfuro
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CL2019003728A1 (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. (divisional solicitud 201701000)
BR112016016416A2 (pt) VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
CR20180538A (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf y un resto de unión a pd1
RU2021124437A (ru) Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
EA201400046A1 (ru) Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
EA201791984A1 (ru) Способы уменьшения уровня fc-содержащих агентов в сыворотке с применением fcrn-антагонистов
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PE20140218A1 (es) Composicion farmaceutica
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
CY1119976T1 (el) Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων
EA201792245A1 (ru) Биоконъюгаты и их применения
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
BR112018071686A2 (pt) exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
UA108778C2 (xx) Протираковий злитий протеїн
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
EA201891990A1 (ru) Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: INSTITUT PASTEUR (FR) ; UNIVERSITE PARIS-SUD (FR) ; IMPERIAL INNOVATIONS LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: INSTITUT PASTEUR (FR) ; UNIVERSITE PARIS-SUD (FR) ; IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]